{"disease":{"id":"naive-advanced-non-small-cell-lung-cancer-with-egfr-sensitive-mutations-egfr-exon-19-deletion-and-exon-21-l858r-mutation-and-symptomatic-brain-metastases","name":"naive advanced non small cell lung cancer with egfr sensitive mutations egfr exon 19 deletion and exon 21 l858r mutation and symptomatic brain metastases"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT07505173","title":"Hippocampus-Protective Radiotherapy Combined With Osimertinib for Symptomatic Brain Metastases in EGFR-Mutated Lung Cancer","phase":"PHASE2","overall_status":"RECRUITING","enrollment_count":74,"lead_sponsor_name":"Tianjin Medical University Cancer Institute and Hospital","has_results":false}],"total":1},"guidelines":[],"source":"Drug Landscape verified database"}